Skip to content
Head to head

Neurocrine Biosciences vs Takeda Pharmaceutical

Side-by-side on the measures that matter, with a plain-English read. Full detail: NBIX · TAK

Updated 10 minutes ago

1-year performance, rebased to 100

NBIX +4.9%TAK +56.6%
Takeda Pharmaceutical edges it on the scoreable measures. Takeda Pharmaceutical has the highest Quant Rating (90); Takeda Pharmaceutical has done best over the past year (+57%); Takeda Pharmaceutical pays the highest dividend yield.
NBIXTAK
Snapshot
SectorDrug Manufacturers - Specialty & Generic--
Last price150.5721.77
Change today-3.84%+1.68%
1-year return+8.3%+57.5%
Market cap$15.24B$69.76B
52-week range122.14 – 186.1213.92 – 22.07
Valuation
P/E (TTM)22.34311.00
P/E percentile, own 5-yr range8th100th
P/B3.931.50
Dividend yield0.00%1.44%
Profitability & growth
EPS (TTM)4.67-0.30
Net profit (TTM)$472.69M$-970.94M
Revenue (TTM)$3.70B$4.69T
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)+41.2%+6.7%
Gross margin97.7%65.8%
Operating margin24.6%14.3%
Net margin19.0%0.9%
Free cash flow (TTM)$1.04B$433.95B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership102.3%51.3%
Insider activity (12mo)16 buy / 30 sell19 buy / 31 sell
Short interest (% of float)5.8%0.1%
Analyst consensus84% buy / 16% hold (19)100% buy (1)
Analyst price target$207 (+38%)$50 (+132%)
StockVane view
StockVane Quant RatingC (51)C (90)
Company
Employees2,00047,029
Founded19921781

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.